Posted by Michael Wonder on 24 Nov 2020
Merck submits applications for licensure of V114, the company’s investigational 15 valent pneumococcal conjugate vaccine, for use in adults to the US FDA and EMA
23 November 2020 - Merck today announced the company has submitted applications to the US FDA and EMA for licensure of V114, Merck’s investigational 15 valent pneumococcal conjugate vaccine, for use in adults 18 years of age and older.
The company awaits acceptance of the submissions by the US and European regulatory authorities.
